期刊
ESC HEART FAILURE
卷 1, 期 2, 页码 94-102出版社
WILEY PERIODICALS, INC
DOI: 10.1002/ehf2.12013
关键词
Heart failure; Heart rate; Inflammatory cytokines; Ventricular remodelling; Gene expression
资金
- Servier
- National Heart, Lung, and Blood Institute [PO1 HL074237-010]
Purpose We tested the hypothesis that heart rate (HR) reduction with ivabradine (IVA) leads to reversal of structural, biochemical, and molecular maladaptations characteristic of the heart failure (HF) state. HR reduction with IVA has been shown to improve left ventricular (LV) systolic function and clinical outcome in patients with HF. Methods Studies were performed in 16 HF dogs produced by intracoronary microembolizations [LV ejection fraction (EF) similar to 35%]. Dogs were randomized to 3-month oral therapy with IVA (30mg Bid, n= 8) or to no therapy (Control, n= 8). LV tissue was obtained from all dogs at the end of therapy and used for molecular, biochemical, and histological studies. Results Average 24-h ambulatory Holter monitoring showed a significant decrease of HR in IVA-treated dogs compared with controls. Compared with pretherapy, LV EF decreased at 3 months in controls (36 +/- 1 vs. 32 +/- 2%, P<0.05) but increased significantly with IVA (40 +/- 3 vs. 35 +/- 3%, P<0.05). Treatment with IVA was associated with (i) improved LV diastolic function; (ii) increased sarcoplasmic reticulum Ca2+ uptake and ATPase activity; (iii) decreased plasma levels of vasoactive neurohormones, natriuretic peptides, and pro-inflammatory cytokines; (iv) normalization of messenger RNA gene expression of multiple signalling pathways; and (v) reduced cardiomyocyte apoptosis and hypertrophy. Conclusion In dogs with HF, HR reduction with IVA reversed many of the structural, biochemical, and molecular maladaptations characteristic of HF. The findings support the concept that HR reduction in HF can elicit benefits, albeit indirect, on a host of maladaptations implicated in the progressive worsening of the HF state.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据